TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26748844

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 139

Group type: COMPARATOR
Intervention: Alpha-blockers
Number of subjects: 139

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 139

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors (ACEi)
Number of subjects: 139
Study: 24998674

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography group (n=160)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (n=160)
Number of subjects: 320
Study: 22342789

Group type: EXPERIMENTAL
Intervention: Early appendectomy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 131
Study: 20485492

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg/day for 5 days)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 900
Study: 17365774

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus tailored brief motivational intervention, quit date behavioral skills counseling, and relapse prevention follow-up session
Number of subjects: 383

Group type: COMPARATOR
Intervention: Nicotine patch plus brief advice using the National Cancer Institute's 4A's model
Number of subjects: 383
Study: 12938828

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment applied twice per day for 7 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Historical control group (no intervention)
Number of subjects: 47
Study: 10720024

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel applied at four sites (left and right arms/shoulders and left and right abdomen)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Transdermal testosterone gel applied at one site (left arm/shoulder)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel applied at four sites
Number of subjects: 9

Group type: COMPARATOR
Intervention: Transdermal testosterone gel applied at one site
Number of subjects: 9
Study: 8740312

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) 300 IU/Kg per week for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 14
Study: 1389644

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 60
Study: 3937968

Group type: EXPERIMENTAL
Intervention: Mitomycin treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no Mitomycin treatment)
Number of subjects: 90
Study: 31406230

Group type: EXPERIMENTAL
Intervention: Bovine MFGM supplemented experimental formula (EF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study: 28202441

Group type: EXPERIMENTAL
Intervention: Euhydrated (EU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypohydration (HY)
Number of subjects: 12
Study: 25875940

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral levodopa-carbidopa (LC-oral)
Number of subjects: 8
Study: 23648698

Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Primary hypertensive patients (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adrenalectomy and Medical therapy (PA patients)
Number of subjects: 180
Study: 21311869

Group type: EXPERIMENTAL
Intervention: Robotic-assisted implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional implantation
Number of subjects: 30
Study: 19106196

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMPC
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17404349

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg subcutaneous abdominal injections twice daily for 16 weeks)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo (subcutaneous abdominal injections twice daily for 16 weeks)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 15082281

Group type: EXPERIMENTAL
Intervention: Preoperative resting ischaemia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Surgical ischaemic preconditioning protocol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Longer ischaemic time
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Increasing values of cycle efficiency
Number of subjects: 33
Study: 10981212

Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: WHOQOL-100
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-transplanted liver disease controls
Number of subjects: 71
Study: 8822986

Group type: EXPERIMENTAL
Intervention: Enalaprilat (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1444500

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil applied three times daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone (6-week taper)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil (open trial)
Number of subjects: 32
Study: 6361300

Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 29624459

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (antioxidant therapy)
Number of subjects: 50
Study: 29649666

Group type: EXPERIMENTAL
Intervention: Active Smoker (AS) group
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Passive Smoker (PS) group
Number of subjects: 320

Group type: COMPARATOR
Intervention: Never Smoker (NS) group
Number of subjects: 320
Study: 27688166

Group type: EXPERIMENTAL
Intervention: Bisphosphonate-coated implants
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (uncoated) implants
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of both implant types
Number of subjects: 16
Study: 24904022

Group type: EXPERIMENTAL
Intervention: Whole grain and legume group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (usual diet with refined rice)
Number of subjects: 99
Study: 22442825

Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19736246

Group type: EXPERIMENTAL
Intervention: 3 g/day MCI-196
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 6 g/day MCI-196
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 9 g/day MCI-196
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All doses of MCI-196
Number of subjects: 120
Study: 18932258

Group type: EXPERIMENTAL
Intervention: ABT-510 20 mg QD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABT-510 50 mg QD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABT-510 100 mg QD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABT-510 10 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABT-510 25 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABT-510 50 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 16187776

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Drug treatment alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Behavior therapy after 6 months of drug treatment alone
Number of subjects: 96
Study: 14507272

Group type: EXPERIMENTAL
Intervention: 2 g of oral calcium carbonate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1 g of oral calcium carbonate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 g of open-label calcium carbonate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10760541

Group type: EXPERIMENTAL
Intervention: Parkinson's disease nurse specialist (PDNS) care
Number of subjects: 108

Group type: COMPARATOR
Intervention: Consultant Neurologist care (control)
Number of subjects: 108
Study: 8777827

Group type: EXPERIMENTAL
Intervention: Low-protein diet with 6.9 g of urea added (LP-U1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-protein diet with 13.7 g of urea added (LP-U2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Reference diet (REF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-protein diets (LP, LP-U1, LP-U2)
Number of subjects: 6
Study: 1519831

Group type: EXPERIMENTAL
Intervention: LTC4
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study: 31999530

Group type: EXPERIMENTAL
Intervention: TEE-pulse measured during laboratory activities (sitting, walking, running, cycling)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Averaging outcome of each activity-type specific equation based on TEE-pulse from laboratory data
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prediction method applied to free-living data
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Activity classification and use of activity-selective prediction equations
Number of subjects: 37
Study: 30639788

Group type: EXPERIMENTAL
Intervention: Bokutoh Positive group
Number of subjects: 5442

Group type: COMPARATOR
Intervention: Bokutoh Negative group
Number of subjects: 5442
Study: 26872548

Group type: EXPERIMENTAL
Intervention: High-dose casein (HP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-dose casein (LP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (C) saline
Number of subjects: 13
Study: 25894705

Group type: EXPERIMENTAL
Intervention: Intensive suicide assessment group
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control assessment group
Number of subjects: 282
Study: 24020602

Group type: EXPERIMENTAL
Intervention: Community care workers (CCWs) trained and supervised to provide TB-HIV/PMTCT services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control CCWs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention CCWs
Number of subjects: 0
Study: 21334697

Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation and NMES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 20
Study: 21030711

Group type: COMPARATOR
Intervention: Aspirin (300 mg)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Medium-dose tinzaparin (100 IU/kg)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: High-dose tinzaparin (175 IU/kg)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Total anterior circulation syndrome
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Partial anterior circulation syndrome
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Large vessel stroke
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Cardioembolic stroke
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: AHTI presence
Number of subjects: 1484
Study: 17545846

Group type: EXPERIMENTAL
Intervention: Immediate stenting of the SVC followed by mediastinal RT within a week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Palliative RT to the mediastinum
Number of subjects: 19
Study: 15792258

Group type: EXPERIMENTAL
Intervention: BiPAP training
Number of subjects: 19
Study: 12213142

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (low-risk/low-benefit)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy surgery (high-risk/high-benefit)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Extracranial-to-intracranial bypass surgery (high-risk/unknown benefit)
Number of subjects: 685
Study: 9799345

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visual correlation (PET+CT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fusion (PET+CT)
Number of subjects: 56
Study: 7609571

Group type: EXPERIMENTAL
Intervention: Sodium loading (1 ml/kg of 10% NaCl infused for 15 minutes)
Number of subjects: 44
Study: 2784648

Group type: EXPERIMENTAL
Intervention: Trimethoprim-dapsone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 78
Study: 68383

Group type: EXPERIMENTAL
Intervention: WRL 105 strain live influenza vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31386106

Group type: EXPERIMENTAL
Intervention: 1 egg per day
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control (no eggs provided)
Number of subjects: 660
Study: 29083331

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg of remifentanil
Number of subjects: 59

Group type: COMPARATOR
Intervention: 2 ml normal saline (control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 59

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 59
Study: 25357090

Group type: EXPERIMENTAL
Intervention: Self-selected priming (379 ± 44 W)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent priming at 100% of Wpeak (376 ± 45 W)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent priming at 150% of Wpeak (374 ± 48 W)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All-out priming (357 ± 45 W)
Number of subjects: 10
Study: 22659021

Group type: EXPERIMENTAL
Intervention: iTBS1200
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 21593114

Group type: EXPERIMENTAL
Intervention: ronacaleret (100, 200, 300, or 400 mg oral once daily)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: teriparatide (20 μg sc once daily)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: alendronate (70 mg once weekly)
Number of subjects: 569

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 569
Study: 19352048

Group type: EXPERIMENTAL
Intervention: Mitiglinide 5 mg
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg
Number of subjects: 381

Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 381
Study: 16333632

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneous injection daily, initiated 12 hours preoperatively)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin (5,000 IU subcutaneous standard heparin initiated 8 hours preoperatively, continued to 15,000 IU per day in three equal dosages every 8 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both Enoxaparin and Heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study: 15587021

Group type: EXPERIMENTAL
Intervention: Immediate loading (same day of surgery)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Delayed loading (next day after surgery)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 19
Study: 11084176

Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐E2, 300 microg daily
Number of subjects: 361

Group type: COMPARATOR
Intervention: Transdermal 17 beta‐E2 (delivering 50 microg/day), two patches per week
Number of subjects: 361
Study: 9333058

Group type: EXPERIMENTAL
Intervention: Triple-dose chlorproguanil-dapsone
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Single-dose chlorproguanil-dapsone
Number of subjects: 448

Group type: COMPARATOR
Intervention: Community surveillance group
Number of subjects: 448
Study: 8437527

Group type: EXPERIMENTAL
Intervention: SBT/AMP 1 g/2 g t.i.d. (n=35 clinically evaluable)
Number of subjects: 73

Group type: COMPARATOR
Intervention: CXM 1.5 g t.i.d. (n=35 clinically evaluable)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SBT/AMP (bacteriological efficacy assessed in 26 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: CXM (bacteriological efficacy assessed in 28 patients)
Number of subjects: 73
Study: 2875812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg bid)
Number of subjects: 24
Study: 29635061

Group type: EXPERIMENTAL
Intervention: 25 mg phenylephrine tannate (equivalent to 10 mg phenylephrine HCl) combined with 200 mg guaifenesin, fasted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg phenylephrine HCl combined with 650 mg acetaminophen, fasted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg phenylephrine HCl, fed
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg phenylephrine HCl, fasted (reference treatment)
Number of subjects: 0
Study: 26616001

Group type: EXPERIMENTAL
Intervention: Ketorolac nasal spray 31.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone/ibuprofen 5/400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocodone/APAP 7.5/500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone/APAP 5/325 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocodone/APAP 10/650 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol HCl/APAP 75/650 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol HCl/APAP 37.5/325 mg
Number of subjects: 0
Study: 24585406

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) followed by gefitinib (250 mg/day) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) alone
Number of subjects: 60
Study: 23109900

Group type: EXPERIMENTAL
Intervention: Genotypes of ACAT‐1 AC, LIPC GA and AA, SCARB1 TT
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Genotypes of ACAT‐1 CC; ACAT‐1 AA and CC
Number of subjects: 1729
Study: 19832720

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (Pip-Tazo, n = 30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMP, n = 32)
Number of subjects: 62
Study: 18677201

Group type: EXPERIMENTAL
Intervention: Group A: early scan (image acquisition initiated within 15 min after injection of the tracer) and no food
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Group D: late scan (image acquisition 30‐60 min after injection of the tracer) and food (two pieces of white bread with butter and a minimum of 450 ml of water)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Early scan (Group A)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Addition of food (Group D)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Rest MPI in 116 of 152 patients
Number of subjects: 152
Study: 16061592

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for 1 week)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 287
Study: 12382302

Group type: EXPERIMENTAL
Intervention: Care provided by a clinical nurse specialist
Number of subjects: 210

Group type: COMPARATOR
Intervention: Inpatient team care
Number of subjects: 210

Group type: COMPARATOR
Intervention: Day patient team care
Number of subjects: 210
Study: 12953977

Group type: EXPERIMENTAL
Intervention: 20 mg gossypol tablet daily until azoospermia occurred, followed by a maintenance dose of 7.5 mg or 10 mg of gossypol orally to alternate subjects.
Number of subjects: 13
Study: 8669221

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 15 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 30 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 45 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 15 micrograms/h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 30 micrograms/h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 45 micrograms/h
Number of subjects: 24
Study: 2148735

Group type: EXPERIMENTAL
Intervention: Chandonium iodide 0.2 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chandonium iodide 0.25 mg/kg
Number of subjects: 50
Study: 6895645

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31727347

Group type: EXPERIMENTAL
Intervention: Chinese square dancing (12-week routine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual lifestyle (control group)
Number of subjects: 66
Study: 29158123

Group type: EXPERIMENTAL
Intervention: Necitumumab continuation therapy
Number of subjects: 476

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin nonprogressors
Number of subjects: 476
Study: 26740030

Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (lectures and traditional case study)
Number of subjects: 63
Study: 23980620

Group type: EXPERIMENTAL
Intervention: Standard-dose stavudine (30-40 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20-30 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 60
Study: 22914501

Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 286

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution
Number of subjects: 286
Study: 19740116

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 17493710

Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 10 microg IMP321
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 30 microg IMP321
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 100 microg IMP321
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flu vaccine plus saline control
Number of subjects: 60